|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | BCLC策略:预后预测和治疗推荐2022版更新显示文摘2018版BCLC预后和治疗推荐策略发布后,肝细胞癌(简称HCC)的研究又取得了重大进展。本次更新基于肝癌各领域的研究进展结果。重点关注影响策略的重要研究进展。虽然近年的研究结果成绩斐然,但将其引入为临床医生和研究者提供行动依据的循证模型指南来说证据效力依然不够确切。本文对该问题进行分析,阐述了为HCC患者制定个体化治疗临床决策所需的批判性思维和专业知识。 | Reig M Forner A Rimola J Ferrer-Fabrega J Burrel M Garcia-Criado A Kelley RK Galle PR Mazzaferro V Salem R Sangro B Singal AG Vogel A Fuster J Ayuso C Bruix J 刘永凡(摘译) 崔笑(摘译) 耿小平(审校) | 2022 | 肝胆外科杂志2022，30，5： | 80 |
| 2 | Liver transplantation in alcoholic liver disease current status and controversies显示文摘Alcoholic cirrhosis remains the second most common indication for liver transplantation.A comprehensive medical and psychosocial evaluation is needed when making a decision to place such patients on the transplant list.Most transplant centers worldwide need a minimum of 6 mo of alcohol abstinence for listing these patients.Patients with alcohol dependence are at high risk for relapse to alcohol use after transplantation(recidivism).These patients need to be identified and require alcohol rehabilitation treatment before transplantation.Recidivism to the level of harmful drinking is reported in about 15%-20%cases.Although,recurrent cirrhosis and graft loss from recidivism is rare,occurring in less than 5%of all alcoholic cirrhosis-related transplants,harmful drinking in the post-transplant pe-riod does impact the long-term outcome.The development of metabolic syndrome with cardiovascular events and de novo malignancy are important contributors to non liver-related mortality amongst transplants for alcoholic liver disease.Surveillance protocols for earlier detection of de novo malignancy are needed to improve the long-term outcome.The need for a minimum of 6 mo of abstinence before listing makes transplant a nonviable option for patients with severe alcoholic hepatitis who do not respond to corticosteroids.Emerging data from retrospective and prospective studies has challenged the 6 mo rule,and beneficial effects of liver transplantation have been reported in select patients with a first episode of severe alcoholic hepatitis who are unresponsive to steroids. | Ashwani K Singal Khushdeep S Chaha Khalid Rasheed Bhupinderjit S Anand | 2013 | World Journal of Gastroenterology2013，19，36： | 12 |
| 3 | Management of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical review显示文摘Nearly one fourth of individuals with human immunodeficiency virus (HIV) infection have hepatitis C virus (HCV) infection in the US and Western Europe. With the availability of highly active antiretroviral therapy and the consequent reduction in opportunistic infections, resulting in the prolongation of the life span of HIV-infected patients, HCV co-infection has emerged as a signif icant factor influencing the survival of HIV patients. Patients with HIV/HCV co-infection have a faster rate of fibrosis progression resulting in more frequent occurrences of cirrhosis, end-stage liver disease, and hepatocellular carcinoma. However, the mechanism of interaction between the two viruses is not completely understood. The treatment for HCV in co-infected patients is similar to that of HCV monoinfection; i.e., a combination of pegylated interferon and ribavirin. The presence of any barriers to antiHCV therapy should be identified and eliminated in order to recruit all eligible patients. The response to treatment in co-infected patients is inferior compared to the response in patients with HCV mono-infection. The sustained virologic response rate is only 38% for genotype-1 and 75% for genotype-2 and -3 infections. Liver transplantation is no longer considered a contraindication for end-stage liver disease in coinfected patients. However, the 5 year survival rate is lower in co-infected patients compared to patients with HCV mono-infection (33% vs 72%, P = 0.07). A better understanding of liver disease in co-infected patients is needed to derive new strategies for improving outcome and survival. | Ashwani K Singal Bhupinderjit S Anand | 2009 | World Journal of Gastroenterology2009，15，30： | 12 |
| 4 | Corticosteroids and pentoxifylline for the treatment of alcoholic hepatitis:Current status显示文摘The treatment of choice for patients with severe alcoholic hepatitis (AH) is use of corticosteroids.Many randomized well designed studies have been reported from all over the world on the use of corticosteroids in the treatment of AH.However,the data on the efficacy of corticosteroids in these patients have been conflicting.Initial meta-analyses also failed to show beneficial effects of corticosteroids.Based on individual data meta-analysis showing clear benefit of corticosteroids amongst patients with severe AH (modified discriminant function of 32 or more),led American College of Gastroenterology to recommend use of corticosteroids as the first line treatment option amongst patients with severe AH.However,corticosteroids are relatively contraindicated amongst patients with severe AH and coexistent sepsis,gastrointestinal bleeding,and acute pancreatitis.These patients may be candidates for second line treatment with pentoxifylline.Further,specific treatment of AH with corticosteroids far from satisfactory with as many as 40%-50% of patients failing to respond to steroids,thus classified as nonresponsive to steroids.The management of these patients is a continuing challenge for physicians.Better treatment modalities need to be developed for this group of patients in order to improve the outcome of patients with severe AH.This article describes at length the available trials on use of corticosteroids and pentoxifylline with their current status.Route of administration,dosage,adverse effects,and mechanisms of action of these two drugs are also discussed.Finally,an algorithm with clinical approach to management of patients who present with clinical syndrome of AH is described. | Ashwani K Singal Ishmeet Walia Anjna Singal Roger D Soloway | 2011 | World Journal of Hepatology2011，3，8： | 7 |
| 5 | Meta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B显示文摘 | A. K. Singal H. Salameh Y.‐F. Kuo R. J. Fontana | 2013 | Aliment Pharmacol Ther2013，，2： | 6 |
| 6 | Liver transplantation in acute alcoholic hepatitis:Current status and future development显示文摘Acute alcoholic hepatitis (AH) is a distinct clinical entity amongst patients with chronic alcohol abuse.Patients with severe AH are at risk of dying in about 20%-25% cases despite specific treatment with corticosteroids and/or pentoxifylline.Clearly,a need for an additional more effective treatment option is unmet currently.Liver transplantation (LT),a definitive treatment option for alcoholic cirrhosis requires 6 mo abstinence.However,this rule cannot be applied to patients with AH as these patients are actively drinking prior to their presentation.Shortage of donors,ethical issues,and fear of recidivism after transplantation with less than 6 mo pretransplant abstinence are some of the reasons behind this rule of 6 mo of abstinence and hesitancy of transplanting patients with AH.These issues are debated at length in this manuscript.Further,retrospective studies have shown that patients undergoing transplantation for alcoholic cirrhosis and having histological changes of AH have been shown to fare as well when compared to patients without these histological changes.Recently,French workers have reported a case matched prospective study showing encouraging data on the usefulness of LT for patients who are non-responders to cortico-steroid and/or pentoxifylline therapy.Future studies are needed to identify patients with severe AH who are going to benefit most with LT.In the light of emerging data on the efficacy of LT in improving survival of patients with severe acute AH who do not respond to corticosteroids,the time is ripe to re-evaluate our policy of LT in patients with AH. | Ashwani K Singal Andrea Duchini | 2011 | World Journal of Hepatology2011，3，8： | 4 |
| 7 | Alcoholic Hepatitis: Current challenges and future directions显示文摘 | Ashwani K. Singal Patrick S. Kamath Gregory J. Gores Vijay H. Shah | 2013 | Clinical Gastroenterology and Hepatology2013，，： | 3 |
| 8 | Mesenteric Venous Thrombosis显示文摘 | Ashwani K. Singal Patrick S. Kamath Ayalew Tefferi | 2013 | Mayo Clinic Proceedings2013，，3： | 3 |
| 9 | Alcoholic hepatitis and concomitant hepatitis C virus infection显示文摘Hepatitis C virus(HCV)infection and alcohol abuse are two most important causes of chronic liver disease in the United States.Alcoholic hepatitis is a unique clinical syndrome among patients with chronic and active alcohol abuse with a potential for high short-term mortality.About 20%of patients presenting with alcoholic hepatitis have concomitant HCV infection.Mortality from alcoholic hepatitis is increased in the presence of concomitant hepatitis C due to synergistic interaction between HCV and alcohol in causing hepatocellular damage.Large prospective randomized studies are needed to develop guidelines on the use of corticosteroids among patients with alcoholic hepatitis and concomitant HCV infection.The impact of antiviral therapy on mortality and outcome in the setting of alcoholic hepatitis remains a novel area for future research. | Mohamed Shoreibah Bhupinderjit S Anand Ashwani K Singal | 2014 | World Journal of Gastroenterology2014，20，34： | 3 |
| 10 | Deep learning in hepatocellular carcinoma:Current status and future perspectives显示文摘Hepatocellular carcinoma(HCC)is among the leading causes of cancer incidence and death.Despite decades of research and development of new treatment options,the overall outcomes of patients with HCC continue to remain poor.There are areas of unmet need in risk prediction,early diagnosis,accurate prognostication,and individualized treatments for patients with HCC.Recent years have seen an explosive growth in the application of artificial intelligence(AI)technology in medical research,with the field of HCC being no exception.Among the various AI-based machine learning algorithms,deep learning algorithms are considered state-of-the-art techniques for handling and processing complex multimodal data ranging from routine clinical variables to high-resolution medical images.This article will provide a comprehensive review of the recently published studies that have applied deep learning for risk prediction,diagnosis,prognostication,and treatment planning for patients with HCC. | Joseph C Ahn Touseef Ahmad Qureshi Amit G Singal Debiao Li Ju-Dong Yang | 2021 | World Journal of Hepatology2021，13，12： | 2 |
| 11 | The Probiotic Preparation, VSL#3 Induces Remission in Patients With Mild-to-Moderately Active Ulcerative Colitis显示文摘 | Ajit Sood Vandana Midha Govind K. Makharia Vineet Ahuja Dinesh Singal Pooja Goswami Rakesh K. Tandon | 2009 | Clinical Gastroenterology and Hepatology2009，，11： | 2 |
| 12 | Alterations in heart sarcolemmal Ca2+-ATPase and Ca2+-binding activities due to oxygen free radicals显示文摘 | M. Kaneko P. K. Singal Dr. N. S. Dhalla | 1990 | Basic Research in Cardiology1990，，1： | 2 |
| 13 | Management practices of hepatitis C virus infected alcoholic hepatitis patients:A survey of physicians显示文摘AIM:To survey gastroenterologists and hepatologists regarding their current views on treating hepatitis C virus(HCV) infected alcoholic hepatitis(AH) patients.METHODS:A sixteen item questionnaire was electronically mailed to gastroenterologists and hepatologists.A reminder was sent after 2 mo to increase the response rate.Participation of respondents was confidential.Accessing secured web site to respond to the questionnaire was considered as informed consent.Responses received on the secured website were downloaded in an excel sheet for data analysis.RESULTS:Analyzing 416 responses to 1556(27% response rate) emails,57% respondents(56% gastroenterologists) reported HCV prevalence > 20% amongst AH patients.Sixty nine percent often treated AH and 46% preferred corticosteroids(CS).Proportion of respondents with consensus(75% or more respondents agreeing on question) on specific management of HCV infected AH were:routine HCV testing(94%),HCV not changing response to CS(80%) or pentoxifylline(91%),no change in approach to treating HCV infected AH(75%).None of respondent variables:age,specialty,annual number of patients seen,and HCV prevalence could predict respondent to be in consensus on any of or all 4 questions.Further,only 4% would choose CS for treating HCV infected AH as opposed to 47% while treating HCV negative AH.CONCLUSION:Gastroenterologists and hepatologists believe that AH patients be routinely checked for HCV.However,there is lack of consensus on choice of drug for treatment and outcome of HCV positive AH patients.Studies are needed to develop guidelines for management of HCV infected AH patients. | Ashwani K Singal Habeeb Salameh Anjna Singal Sarat C Jampana Daniel H Freeman Karl E Anderson Don Brunder | 2013 | World Journal of Gastrointestinal Pharmacology and Therapeutics2013，4，2： | 2 |
| 14 | Mesenteric Venous Thrombosis显示文摘 | Bashar Hmoud Ashwani K. Singal Patrick S. Kamath | 2014 | Journal of Clinical and Experimental Hepatology2014，，： | 2 |
| 15 | Is MRCP equivalent to ERCP for diagnosing biliary obstruction in orthotopic liver transplant recipients? A meta-analysis显示文摘 | Jennifer E. Jorgensen Akbar K. Waljee Michael L. Volk Christopher J. Sonnenday Grace H. Elta Mahmoud M. Al-Hawary Amit G. Singal Jason R. Taylor B. Joseph Elmunzer | 2011 | Gastrointestinal Endoscopy2011，，5： | 2 |
| 16 | Antiviral Therapy Reduces Risk of Hepatocellular Carcinoma in Patients With Hepatitis C Virus–Related Cirrhosis显示文摘 | Ashwani K. Singal Amanpal Singh Sathya Jaganmohan Praveen Guturu Rajasekhara Mummadi Yong–Fang Kuo Gagan K. Sood | 2010 | Clinical Gastroenterology and Hepatology2010，，2： | 2 |
| 17 | Leprosy in post-elimination era in India: diffi- cuh journey ahead 显示文摘 | Singal A Sonthalia S | 2013 | Indian J Dermatol2013，58，6： | 1 |
| 18 | Mathematical basis and validation of the full cavitation model 显示文摘 | SINGAL A K ATHAVALE M M LI H Y | 2002 | Journal of Fluids Engineering2002，124，3： | 1 |
| 19 | Modulation of oxidative stress by a selective inhibition of angiotensin Ⅰ type 1 receptors in MI-rats 显示文摘 | Khaper N Singal PK | 2001 | J Am Coll Cardiol2001，37，5： | 1 |
| 20 | DNA methylation显示文摘 | Singal R Ginder GD | 1999 | Blood1999，93，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员